Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Amortizatization of Intangibles (2019 - 2025)

UroGen Pharma (URGN) has disclosed Amortizatization of Intangibles for 7 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles rose 347.42% year-over-year to $1.7 million, compared with a TTM value of $2.1 million through Dec 2025, up 145.51%, and an annual FY2025 reading of $2.1 million, up 145.51% over the prior year.
  • Amortizatization of Intangibles was $1.7 million for Q4 2025 at UroGen Pharma, up from -$564000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $1.7 million in Q4 2025 and bottomed at -$961000.0 in Q1 2024.
  • Average Amortizatization of Intangibles over 5 years is $219600.0, with a median of $220000.0 recorded in 2023.
  • The sharpest move saw Amortizatization of Intangibles soared 2320.0% in 2022, then plummeted 2215.15% in 2024.
  • Year by year, Amortizatization of Intangibles stood at -$476000.0 in 2021, then soared by 61.34% to -$184000.0 in 2022, then surged by 117.93% to $33000.0 in 2023, then tumbled by 2215.15% to -$698000.0 in 2024, then surged by 347.42% to $1.7 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for URGN at $1.7 million in Q4 2025, -$564000.0 in Q3 2025, and $516000.0 in Q2 2025.